Monika M Gladka1,2. 1. Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Centre, PO Box 85164, 3508 AD, Utrecht, The Netherlands. m.gladka@hubrecht.eu. 2. Department of Medical Biology, Amsterdam University Medical Center, Amsterdam, The Netherlands. m.gladka@hubrecht.eu.
Abstract
PURPOSE OF THE REVIEW: Cardiovascular disease remains the leading cause of death worldwide, resulting in cardiac dysfunction and, subsequently, heart failure (HF). Single-cell RNA sequencing (scRNA-seq) is a rapidly developing tool for studying the transcriptional heterogeneity in both healthy and diseased hearts. Wide applications of techniques like scRNA-seq could significantly contribute to uncovering the molecular mechanisms involved in the onset and progression to HF and contribute to the development of new, improved therapies. This review discusses several studies that successfully applied scRNA-seq to the mouse and human heart using various methods of tissue processing and downstream analysis. RECENT FINDINGS: The application of scRNA-seq in the cardiovascular field is continuously expanding, providing new detailed insights into cardiac pathophysiology. Increased understanding of cardiac pathophysiology on the single-cell level will contribute to the development of novel, more effective therapeutic strategies. Here, we summarise the possible application of scRNA-seq to the adult mammalian heart.
PURPOSE OF THE REVIEW: Cardiovascular disease remains the leading cause of death worldwide, resulting in cardiac dysfunction and, subsequently, heart failure (HF). Single-cell RNA sequencing (scRNA-seq) is a rapidly developing tool for studying the transcriptional heterogeneity in both healthy and diseased hearts. Wide applications of techniques like scRNA-seq could significantly contribute to uncovering the molecular mechanisms involved in the onset and progression to HF and contribute to the development of new, improved therapies. This review discusses several studies that successfully applied scRNA-seq to the mouse and human heart using various methods of tissue processing and downstream analysis. RECENT FINDINGS: The application of scRNA-seq in the cardiovascular field is continuously expanding, providing new detailed insights into cardiac pathophysiology. Increased understanding of cardiac pathophysiology on the single-cell level will contribute to the development of novel, more effective therapeutic strategies. Here, we summarise the possible application of scRNA-seq to the adult mammalian heart.
Authors: Allon M Klein; Linas Mazutis; Ilke Akartuna; Naren Tallapragada; Adrian Veres; Victor Li; Leonid Peshkin; David A Weitz; Marc W Kirschner Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Evan Z Macosko; Anindita Basu; Rahul Satija; James Nemesh; Karthik Shekhar; Melissa Goldman; Itay Tirosh; Allison R Bialas; Nolan Kamitaki; Emily M Martersteck; John J Trombetta; David A Weitz; Joshua R Sanes; Alex K Shalek; Aviv Regev; Steven A McCarroll Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Dominic Grün; Anna Lyubimova; Lennart Kester; Kay Wiebrands; Onur Basak; Nobuo Sasaki; Hans Clevers; Alexander van Oudenaarden Journal: Nature Date: 2015-08-19 Impact factor: 49.962
Authors: Daniel M DeLaughter; Alexander G Bick; Hiroko Wakimoto; David McKean; Joshua M Gorham; Irfan S Kathiriya; John T Hinson; Jason Homsy; Jesse Gray; William Pu; Benoit G Bruneau; J G Seidman; Christine E Seidman Journal: Dev Cell Date: 2016-11-10 Impact factor: 12.270
Authors: David Y Barefield; Sean Yamakawa; Ibrahim Tahtah; Jordan J Sell; Michael Broman; Brigitte Laforest; Sloane Harris; Alejandro Alvarez-Arce; Kelly N Araujo; Megan J Puckelwartz; J Andrew Wasserstrom; Glenn I Fishman; Elizabeth M McNally Journal: J Mol Cell Cardiol Date: 2022-05-06 Impact factor: 5.763